SABCS 2022




Ribociclib in combination with letrozole induces potent antiproliferative effects in comparison to chemotherapy in patients with HR-positive/HER2-negative breast cancer. Read More ›


In vitro study finds combination approaches with alpelisib in triple-negative breast cancer harboring PIK3CA mutations provide synergistic effect. Read More ›

Clinical trial assessing the additive benefit of alpelisib to fulvestrant in treatment-refractory HR-positive/HER2-negative ABC currently enrolling patients. Read More ›

Results from the SOLAR-1 study demonstrate that only PIK3CA mutations can predict sensitivity to alpelisib in patients with HR-positive/HER2-negative breast cancer. Read More ›

Findings from Cohort A of the BYLieve study suggest that treatment of HR-positive/HER2-negative breast cancer with PIK3CA mutation drivers with alpelisib plus fulvestrant may lead to long-term disease control. Read More ›

Clinical trial assessing alpelisib plus tucatinib in HER2-positive mBC with PIK3CA mutations is currently enrolling patients. Read More ›

Page 1 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse‚ÄďAPN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications